The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Arix to Present at the Jefferies Virtual London Healthcare Conference

12 Nov 2020 07:00

Arix Bioscience PLC (ARIX) Arix to Present at the Jefferies Virtual London Healthcare Conference 12-Nov-2020 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

 

Arix to Present at the Jefferies Virtual London Healthcare Conference

 

LONDON, 12 November 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that Dr. Naseem Amin, Executive Chairman, is scheduled to participate in an analyst led fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, 17 November 2020, at 10:35am GMT.

 

A live webcast of the fireside chat will be available on the investor relations section of Arix's website at https://arixbioscience.com/investor-relations/events-presentations. After the conference, an archived replay will be available on the company's website at the same address.

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

Optimum Strategic Communications

Supriya Mathur, Shabnam Bashir, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

 

For more information please visit: www.arixbioscience.com


ISIN:GB00BD045071
Category Code:MSCM
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:87702
EQS News ID:1147540
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
16th Mar 20237:01 amEQSUnaudited NAV for February 2023
14th Feb 20236:19 pmEQSPortfolio company Disc Medicine announces $62.5 million financing
6th Feb 20236:00 pmEQSDirector/PDMR Shareholding
6th Feb 20235:00 pmEQSDirector/PDMR Shareholding
6th Feb 20238:00 amEQSUnaudited NAV for January 2023
6th Feb 20237:00 amEQSUnaudited NAV for January 2023
30th Jan 20238:00 amEQSUnaudited NAV for December 2022
30th Jan 20237:00 amEQSUnaudited NAV for December 2022
26th Jan 20238:00 amEQSBoard Change
26th Jan 20237:00 amEQSBoard Change
5th Jan 20235:20 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
5th Jan 20234:21 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
30th Dec 20228:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
30th Dec 20227:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
12th Dec 20228:00 amEQSUnaudited NAV for November 2022
12th Dec 20227:01 amEQSUnaudited NAV for November 2022
6th Dec 20228:00 amEQSArix to Present at Mello Investment Trusts & Funds
6th Dec 20227:00 amEQSArix to Present at Mello Investment Trusts & Funds
1st Dec 20227:45 amRNSDirector/PDMR Shareholding
9th Nov 20228:00 amEQSUnaudited NAV for October 2022
9th Nov 20227:00 amEQSUnaudited NAV for October 2022
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
20th Oct 20224:30 pmEQSHolding(s) in Company
20th Oct 20224:30 pmEQSHolding(s) in Company
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
3rd Oct 20224:32 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
3rd Oct 20224:31 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
15th Sep 20227:01 amEQSUnaudited NAV for August 2022
15th Sep 20227:00 amEQSUnaudited NAV for August 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20227:01 amEQSInterim Results for the Six Months Ended 30 June 2022
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:00 amEQSInterim Results for the Six Months Ended 30 June 2022
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jun 20224:45 pmEQSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.